ITGAX and neoplasm: GM-CSF 1 IL-4 treatment caused BM (19.7 ± 7.5% of cells) and spleen (33.1 ± 6.9% of cells) M-MDSCs to significantly gain CD11c expression whereas tumor M-MDSCs were unresponsive to these treatments (1.5 ± 1.0% of cells) (Fig. 3B).